james yu

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. James Yu is an Assistant Professor at The University of Texas MD Anderson Cancer Center in the United States. His research focuses on oncology, particularly in the areas of pancreatic ductal adenocarcinoma, colorectal cancer, and hepatocellular carcinoma. Recent publications include studies on the impact of adjuvant chemotherapy on patient survival, the role of circulating tumor DNA in detecting early cancer recurrence, and innovative combinatorial approaches in cancer immunotherapy.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Tiago Biachi de Castria

Associate Professor

University of South Florida

UNITED STATES

View details

Eric Mortensen

University of Connecticut School of Medicine

UNITED STATES

View details

Aiwu He

Associate Professor

Georgetown University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

james yu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy

Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer

Marijuana Use May Be Associated with Reduced Prevalence of Prostate Cancer: A National Survey on Drug Use and Health Study from United States of America

Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma

Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy

Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib

Collaborators (3)

Tiago Biachi de Castria

Eric Mortensen

Aiwu He

Make your next move.